Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

Objective: Lp (a)(lipoprotein [a]) concentrations are associated with atherosclerotic
cardiovascular disease (ASCVD), and new therapies that enable potent and specific …

The gut microbiome plays an important role in human health and influences the
development of chronic diseases ranging from metabolic disease to gastrointestinal …

Importance Lipoprotein (a)(Lp [a]) is a low-density lipoprotein (LDL) cholesterol–like particle
bound to apolipoprotein (a). This novel marker of cardiovascular disease acts through …

Background Lipoprotein (a) levels are genetically determined and, when elevated, are a risk
factor for cardiovascular disease and aortic stenosis. There are no approved pharmacologic …

There is a need to identify high-risk features that predict early-onset atherosclerotic
cardiovascular disease (ASCVD). The authors provide insights to help clinicians identify and …

Background Lipoprotein (a) concentration is associated with cardiovascular events.
Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein (a) …

Introduction Dyslipidemia may be defined as increased levels of serum total cholesterol
(TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), or a decreased serum …